Latest posts
-
BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™ with Venture Medical
Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement
-
BioStem Technologies Engages PCG Advisory for Strategic Investor Relations
POMPANO BEACH, FLORIDA, September 18, 2023 – BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with